Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Indiana
Clinical trial register · United States · industry-sponsored

Clinical Trials in Indiana, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 5299 Florida 4438 Illinois 2485 Georgia 2364 Arizona 2242
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company49 AbbVie41 AstraZeneca41 Janssen Research & Development, LLC39 Merck Sharp & Dohme LLC31
State
California5299 Florida4438 Illinois2485 Georgia2364 Arizona2242
All 51 states
Target enrolment
to

Trials with a site in Indiana

1122 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Missouri
2027-11-23
Not yet open
Nuvation Bio Inc.
Phase 2
40
California, Connecticut, Florida, Indiana, New Jersey, New York, Ohio
2027-03
Not yet open
Aquilo Sports, LLC
Not applicable
40
Indiana
2027-01-01
Not yet open
Microbio Co Ltd
Observational
1,500
Indiana, Maryland, New Mexico, Tennessee, Texas
2026-11
Not yet open
Smith & Nephew, Inc.
Not applicable
330
Colorado, Georgia, Indiana
2026-10-30
Recruiting
GlaxoSmithKline
Phase 3
3,000
Arizona, California, Florida, Idaho, Indiana, Kansas, New York, South Carolina
2026-10-01
Not yet open
P+F Products + Features USA Inc.
Not applicable
780
Alabama, Arizona, California, District of Columbia, Florida, Illinois, Indiana, Kansas
2026-10
Recruiting
Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction
NCT07729137Corneal Edema, Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy
Emmecell
Phase 2
121
California, Florida, Georgia, Illinois, Indiana, Kansas, Minnesota, Missouri
2026-10
Recruiting
Knee Cartilage Repair Registry
NCT07786207Knee Injuries, Joint Surface Knee Lesions
Smith & Nephew, Inc.
Observational
1,000
Colorado, District of Columbia, Indiana, Kentucky, Oklahoma, Pennsylvania
2026-09-23
Recruiting
Novo Nordisk A/S
Phase 3
650
California, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana, Missouri
2026-09-22
Recruiting
Pelage Pharmaceuticals, Inc.
Phase 2/3
600
Alabama, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Minnesota
2026-09-21
Recruiting
4D Molecular Therapeutics
Phase 3
514
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2026-09-18
Recruiting
Boehringer Ingelheim
Phase 3
466
Alabama, California, Connecticut, Florida, Indiana, Kansas, Michigan, Minnesota
2026-09-17
Recruiting
Corvus Pharmaceuticals, Inc.
Phase 1
25
Indiana, Kentucky, Massachusetts, New York, North Dakota, Ohio, Pennsylvania, Tennessee
2026-09-17
Recruiting
CSL Behring
Phase 3
63
California, Colorado, Florida, Indiana, Maryland, New Jersey, New York, North Carolina
2026-09-15
Recruiting
AstraZeneca
Phase 3
200
Arizona, California, Florida, Georgia, Indiana, Louisiana, Maryland, North Carolina
2026-09-10
Recruiting
Novartis Pharmaceuticals
Phase 2
259
Alabama, California, Florida, Georgia, Indiana, Kansas, Louisiana, Michigan
2026-09-10
Recruiting
Pfizer
Phase 3
600
Arizona, California, Connecticut, District of Columbia, Idaho, Indiana, New Jersey, Ohio
2026-09-09
Recruiting
Device for Treating Generalized Anxiety
NCT07819773Generalized Anxiety Disorder (GAD)
BTL Industries Ltd.
Not applicable
40
Colorado, Illinois, Indiana
2026-09-09
Not yet open
Amgen
Phase 3
180
Arkansas, California, Indiana, Texas
2026-09-07
Not yet open
Abiomed Inc.
Not applicable
250
Florida, Indiana, Minnesota, Missouri, New Jersey, North Carolina, Pennsylvania, Tennessee
2026-09-01
By invitation
OsteoFlo HydroFiber Ambispective Evaluation
NCT07784673OsteoFlo HydroFiber
SurGenTec LLC
Observational
100
Illinois, Indiana
2026-09-01
Not yet open
Spyre Therapeutics, Inc.
Phase 2
150
California, Indiana, Kentucky, Louisiana, Massachusetts, New York, South Carolina, Texas
2026-09
Not yet open
A Trial to Assess the Safety and Effectiveness of an Anatomic Total Shoulder System
NCT07812324Shoulder Arthroplasty, Total Shoulder Arthroplasty
Medacta USA
Not applicable
286
Arizona, Florida, Indiana, Maryland, New Hampshire, New York, Oregon, Pennsylvania
2026-09
Not yet open
Eli Lilly and Company
Phase 3
150
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2026-09
Recruiting
Vaderis Therapeutics AG
Phase 3
240
Illinois, Indiana, Minnesota, Missouri
2026-09
Not yet open
Flaus, Inc
Not applicable
80
Indiana
2026-08-31
Recruiting
Novo Nordisk A/S
Phase 3
950
Alabama, California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana
2026-08-31
Recruiting
Axsome Therapeutics, Inc.
Phase 3
705
Arkansas, California, Florida, Georgia, Illinois, Indiana, Missouri, New York
2026-08-27
Recruiting
Eli Lilly and Company
Phase 2
120
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts
2026-08-27
Recruiting
Pfizer
Phase 3
400
Arizona, California, Florida, Indiana, Massachusetts, Michigan, Missouri, Nebraska
2026-08-26
Recruiting
Edgewise Therapeutics, Inc.
Phase 2
90
Alabama, California, Illinois, Indiana, Kentucky, Louisiana, Maryland, Michigan
2026-08-25
Recruiting
Pfizer
Phase 3
1,375
Arizona, California, Georgia, Indiana, Michigan, Oklahoma, Pennsylvania, Tennessee
2026-08-24
Recruiting
Novartis Pharmaceuticals
Phase 3
180
Florida, Georgia, Indiana, New York, Ohio, South Carolina, Texas
2026-08-24
Recruiting
Novo Nordisk A/S
Phase 3
1,778
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2026-08-24
Recruiting
AbbVie
Phase 3
300
California, Florida, Idaho, Indiana, Nebraska, Ohio, Texas, Virginia
2026-08-24
Recruiting
Flaus, Inc
Not applicable
80
Indiana
2026-08-18
Recruiting
Medtronic Cardiac Ablation Solutions
Not applicable
260
Indiana, New York, North Carolina, Ohio, Texas
2026-08-17
Recruiting
Genmab
Phase 3
960
Arkansas, California, Georgia, Indiana, Missouri, Washington
2026-08-11
Recruiting
Regeneron Pharmaceuticals
Phase 3
15,364
Alabama, Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana
2026-08-10
Recruiting
Eli Lilly and Company
Phase 2
606
Alabama, California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan
2026-08-07
Recruiting
Sanofi
Observational
350
Indiana, North Carolina, Texas
2026-08-06
Recruiting
Novo Nordisk A/S
Phase 3
285
Georgia, Hawaii, Illinois, Indiana, Kentucky, North Carolina, South Carolina, Virginia
2026-08-04
Recruiting
Novo Nordisk A/S
Phase 3
80
Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Michigan, New York
2026-08-04
Recruiting
ORIC Pharmaceuticals
Phase 3
600
Florida, Indiana, Michigan, North Carolina, Ohio, South Carolina, Tennessee, Texas
2026-08-03
Recruiting
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NCT07516093B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsBexobrutideg·Pirtobrutinib
Nurix Therapeutics, Inc.
Phase 3
620
Georgia, Indiana, Tennessee, Texas, Virginia
2026-08-03
Recruiting
Study of Resmetirom in Children and Adolescents With MASH
NCT07763015MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugResmetirom
Madrigal Pharmaceuticals, Inc.
Phase 2
61
Indiana
2026-08-01
Not yet open
TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study)
NCT07684313Heart Valve Diseases, Heart Diseases, Cardiovascular Diseases, Tricuspid Valve Disease
Edwards Lifesciences
Observational
75
Indiana
2026-08
Recruiting
Pfizer
Phase 3
336
California, Florida, Illinois, Indiana, Iowa, Maryland, Michigan, North Carolina
2026-07-30
Recruiting
Verastem, Inc.
Phase 2
150
California, Florida, Indiana, Michigan, Missouri, New Jersey, New York, North Carolina
2026-07-28
Recruiting
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
NCT07601425Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
DrugATV-1601
Atavistik Bio, Inc
Phase 1/2
100
Arizona, Georgia, Indiana, Massachusetts, Minnesota, Utah
2026-07-27
Recruiting
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
NCT07734649Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
DrugHMPV vaccine
Sanofi
Phase 1/2
2,400
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana
2026-07-22
Recruiting
Gilead Sciences
Phase 1
112
California, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Nevada, New Jersey
2026-07-22
Recruiting
Agios Pharmaceuticals, Inc.
Phase 3
159
Indiana, Michigan, Mississippi
2026-07-21
Recruiting
Novartis Pharmaceuticals
Phase 3
710
Arkansas, California, Florida, Illinois, Indiana, Nebraska, New York, North Carolina
2026-07-10
Recruiting
Regeneron Pharmaceuticals
Phase 3
7,050
Alabama, Arizona, Arkansas, California, Florida, Indiana, Louisiana, North Carolina
2026-07-10
Recruiting
Intalight Reference Database Protocol for VG200D
NCT07751484The Focus of This Study is to Collect OCT Data on Normal Eyes
Intalight, Inc
Observational
350
California, Illinois, Indiana
2026-07-08
Recruiting
Synchronized Diaphragmatic Stimulation in Symptomatic Heart Failure
NCT06552637Heart Failure With Reduced Ejection Fraction
VisCardia Inc.
Not applicable
270
Indiana, Oklahoma, Pennsylvania, Texas
2026-07-08
Recruiting
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
NCT07602842Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
InduPro, Inc.
Phase 1/2
132
California, Florida, Indiana, New York, Texas
2026-07-08
Recruiting
AstraZeneca
Phase 3
2,000
Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Iowa
2026-07-06
Recruiting
AbbVie
Phase 3
531
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2026-07-02
Recruiting
Neurocrine Switzerland GmbH
Phase 2
20
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Michigan, Minnesota
2026-07-01
Recruiting
Expedition Therapeutics, Inc
Phase 2
600
Arizona, California, Colorado, Florida, Georgia, Indiana, Kansas, Minnesota
2026-06-30
Recruiting
Enveda Therapeutics
Phase 2
200
California, Florida, Indiana, Texas
2026-06-29
Recruiting
A Study of MZE782 in Adults With PKU
NCT07694440Phenylketonuria (PKU)
Maze Therapeutics
Phase 2
38
California, Illinois, Indiana, Kentucky, Pennsylvania, Tennessee
2026-06-23
Recruiting
Novo Nordisk A/S
Phase 2
300
Alabama, California, Florida, Indiana, Kansas, Maryland, North Carolina, North Dakota
2026-06-22
Recruiting
Janssen Research & Development, LLC
Observational
150
Alabama, Arkansas, California, Colorado, Florida, Illinois, Indiana, Michigan
2026-06-12
Recruiting
Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve Reconstruction
NCT07657182Peripheral Nerve Injury, Peripheral Nerve Discontinuity, Mixed Peripheral Nerve Injury, Motor Peripheral Nerve Injury
Axogen Corporation
Phase 4
178
Florida, Indiana, Missouri
2026-06-11
Recruiting
Pfizer
Phase 3
954
California, Florida, Illinois, Indiana, Kentucky, Maryland, Michigan, Nebraska
2026-06-10
Active, closed
Novo Nordisk A/S
Phase 2
233
Alabama, California, Florida, Illinois, Indiana, Kentucky, Maryland, Missouri
2026-06-09
Recruiting
Rapport Therapeutics Inc.
Phase 3
333
California, Florida, Georgia, Idaho, Indiana, Maryland, New Jersey, New York
2026-06-05
Recruiting
Genentech, Inc.
Phase 2
162
California, Connecticut, Florida, Indiana, Michigan, Minnesota, Missouri, Nebraska
2026-06-05
Recruiting
Harmony Biosciences Management, Inc.
Phase 3
258
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-06-04
Recruiting
InventisBio Co., Ltd
Phase 2
75
Alabama, Arizona, California, Florida, Georgia, Idaho, Indiana, Kentucky
2026-06-03
Not yet open
Evaluation of the Efficacy, Safety, and Tolerability of LevoCept
NCT04457076Contraception, Women at Risk for Pregnancy
Sebela Women's Health Inc.
Phase 3
1,525
California, Colorado, Georgia, Hawaii, Indiana, Minnesota, Missouri, Nevada
2026-06-01
Recruiting
Bayer
Phase 3
117
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2026-06-01
Recruiting
Allterum Therapeutics, Inc
Phase 1
24
Colorado, Indiana, New York, Ohio, Pennsylvania, Texas
2026-06-01
Recruiting
Biocomposites Ltd
Not applicable
139
California, Indiana, Maryland, New Jersey
2026-06
Recruiting
BioMarin Pharmaceutical
Phase 4
12
California, Colorado, Florida, Illinois, Indiana, Minnesota, New York, Oregon
2026-05-29
Recruiting
Pfizer
Phase 4
400
California, Florida, Indiana, Massachusetts, Michigan, Minnesota, Mississippi, Nevada
2026-05-28
Recruiting
Amgen
Phase 3
304
California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland, Massachusetts
2026-05-27
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Connecticut, Florida, Georgia, Illinois, Indiana, Maryland, New Jersey, New York
2026-05-27
Recruiting
Shanghai Henlius Biotech
Phase 1
258
Arkansas, Florida, Indiana, Louisiana, Texas, Washington
2026-05-25
Recruiting
Claris Biotherapeutics, Inc.
Observational
500
Indiana, Kansas, Kentucky, Minnesota, Oregon, Tennessee, Texas
2026-05-22
Recruiting
Eli Lilly and Company
Phase 3
550
Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa
2026-05-22
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 2
350
Arizona, California, Colorado, Connecticut, Florida, Indiana, Kansas, Massachusetts
2026-05-20
Recruiting
Alpha Cognition, Inc
Phase 4
150
California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri
2026-05-20
Recruiting
Lumos Pharma
Phase 3
150
Alabama, California, Colorado, District of Columbia, Florida, Indiana, Iowa, Louisiana
2026-05-20
Recruiting
Hanmi Pharmaceutical Company Limited
Phase 2
180
Arizona, Florida, Georgia, Indiana, Missouri, Nebraska, Nevada, North Carolina
2026-05-18
Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
NCT07486934Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease
DrugZeleciment basivarsen
Dyne Therapeutics
Phase 3
150
California, Florida, Georgia, Indiana, Maryland, Missouri, New York, North Carolina
2026-05-14
Recruiting
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
NCT07579702Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Insulet Corporation
Not applicable
200
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Massachusetts, Michigan
2026-05-13
Recruiting
Eli Lilly and Company
Phase 2
600
Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Kentucky
2026-05-13
Recruiting
Janssen Research & Development, LLC
Phase 1
360
Indiana, Michigan, New Jersey, New York, Tennessee, Texas
2026-05-13
Recruiting
Dompé Farmaceutici S.p.A
Phase 2
417
Arizona, California, Florida, Georgia, Indiana, Minnesota, Missouri, North Carolina
2026-05-12
Recruiting
A Study to Assess the Safety, Tolerability and Efficacy of ION775
NCT07604974Hypertriglyceridemia, Severe Hypertriglyceridemia
Ionis Pharmaceuticals, Inc.
Phase 2
72
California, Colorado, Florida, Georgia, Indiana, Kentucky, Michigan, Ohio
2026-05-12
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
390
California, Colorado, Delaware, Illinois, Indiana, Missouri, Ohio, Oregon
2026-05-11
Recruiting
Grifols Biologicals, LLC
Phase 3
49
Florida, Indiana, Maine, Ohio, Washington
2026-05-11
Recruiting
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NCT07214532Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)
Natera, Inc.
Not applicable
725
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana
2026-05-08
Recruiting
Eli Lilly and Company
Phase 2
531
Arizona, California, Florida, Illinois, Indiana, Kentucky, Michigan, Minnesota
2026-05-06
Recruiting
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
DrugXNW27011
Astellas Pharma Global Development, Inc.
Phase 1/2
150
Alabama, California, Florida, Georgia, Indiana, Michigan, New Jersey, New York
2026-05-04
Recruiting
Altesa Biosciences, Inc.
Phase 2
180
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2026-05-01
Not yet open
Optimization for Toric Contact Lenses
NCT07557030Astigmatism, Ametropia
CooperVision International Limited (CVIL)
Not applicable
45
Indiana
2026-05
Recruiting
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637Treatment-resistant Depression (TRD)
Alto Neuroscience
Phase 2
178
Alabama, Arizona, California, Florida, Georgia, Indiana, Maryland, Massachusetts
2026-05
Recruiting
Oncolytics Biotech
Phase 2
60
Alabama, California, Florida, Georgia, Idaho, Illinois, Indiana, Michigan
2026-04-30
Recruiting
Insulet Corporation
Not applicable
350
California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana, Massachusetts
2026-04-30
Recruiting
Eli Lilly and Company
Phase 2
342
Arizona, California, Florida, Illinois, Indiana, Kentucky, New York, Ohio
2026-04-29
Recruiting
Hoffmann-La Roche
Phase 3
360
California, Colorado, Florida, Indiana, Iowa, Michigan, Minnesota, Texas
2026-04-27
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)
Liquidia Technologies, Inc.
Phase 3
344
Arizona, California, Colorado, Florida, Illinois, Indiana, New York, Oregon
2026-04-23
Active, closed
Novo Nordisk A/S
Phase 3
606
Alabama, California, Florida, Illinois, Indiana, North Carolina, Pennsylvania, Rhode Island
2026-04-21
Recruiting
Colgate Palmolive
Phase 4
100
Indiana
2026-04-20
Recruiting
Agios Pharmaceuticals, Inc.
Phase 1
20
Indiana, Pennsylvania, Texas
2026-04-17
Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Vitiligo, Non-Segmental Vitiligo (NSV)
DrugLY4005130
Eli Lilly and Company
Phase 2
66
Arizona, California, Florida, Georgia, Indiana, Massachusetts, Michigan, New Hampshire
2026-04-14
Recruiting
AstraZeneca
Phase 3
245
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2026-04-13
Recruiting
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
NCT07403721Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen
Phase 1
464
California, Illinois, Indiana, Maine, Tennessee, Texas
2026-04-08
Active, closed
Kailera
Phase 2
306
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Louisiana
2026-04-06
Recruiting
Regeneron Pharmaceuticals
Phase 3
2,628
Alabama, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Michigan
2026-04-03
Active, closed
Registry Analysis of Deceased Donor Kidney Transplant Outcomes
NCT07530991Normothermic Machine Perfusion (NMP) of Deceased Donor Kidneys
Chris Jaynes
Observational
3,500
Indiana
2026-04-01
Not yet open
Robert Pickett
Not applicable
135
Indiana, Tennessee
2026-04-01
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
202
California, Florida, Indiana, Louisiana, Michigan, North Carolina, Texas
2026-04-01
Recruiting
Zimmer Biomet-RibFix Titan
NCT07485829Rib Fracture, Rib Fracture Multiple
Zimmer Biomet
Observational
54
Indiana
2026-03-31
Recruiting
HALEON
Not applicable
60
Indiana
2026-03-30
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
DrugsTiespectus·Eylea·Aflibercept
EyeBiotech Ltd.
Phase 2/3
960
Arizona, Arkansas, California, Florida, Illinois, Indiana, Maryland, Michigan
2026-03-27
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana
2026-03-26
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
California, Connecticut, District of Columbia, Florida, Indiana, Iowa, Maryland, Michigan
2026-03-26
Recruiting
Zydus Therapeutics Inc.
Phase 3
386
Georgia, Indiana, Texas
2026-03-24
Recruiting
Zenas BioPharma (USA), LLC
Phase 3
990
Arizona, California, Florida, Indiana, Kansas, Massachusetts, Michigan, Missouri
2026-03-23
Recruiting
Friendi.fi Corporation
Not applicable
38
Indiana, Kentucky
2026-03-21
Recruiting
Priovant Therapeutics, Inc.
Phase 2/3
342
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2026-03-19
Recruiting
Quoin Pharmaceuticals
Phase 2/3
16
California, Connecticut, Indiana, Massachusetts, Texas
2026-03-19
Recruiting
Amgen
Phase 3
71
Indiana
2026-03-18
Recruiting
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07154290Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
DrugsMarlotamig·Ubamatamab·Sarilumab
Regeneron Pharmaceuticals
Phase 2
300
Alabama, Arizona, California, Delaware, District of Columbia, Florida, Illinois, Indiana
2026-03-18
Recruiting
SymBio Pharmaceuticals
Phase 3
180
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2026-03-17
Recruiting
Harmony Biosciences Management, Inc.
Phase 3
248
Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Michigan
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 3
850
Alabama, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Kentucky
2026-03-16
Recruiting
Astellas Pharma Global Development, Inc.
Phase 2
240
Arkansas, Illinois, Indiana, Michigan, New Jersey, New York, Pennsylvania, South Carolina
2026-03-12
Recruiting
Bristol-Myers Squibb
Phase 3
750
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-03-12
Recruiting
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
NCT07457918Common Warts (Verruca Vulgaris), Common Warts, Human Papilloma Virus (HPV), Warts
Verrica Pharmaceuticals Inc.
Phase 3
600
Florida, Indiana, Ohio, Texas
2026-03-11
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Alabama, California, Florida, Indiana, Michigan, Nebraska, Nevada, New York
2026-03-09
Active, closed
Kailera
Phase 2
264
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2026-03-04
Recruiting
TOUCH® CMC 1 New Enrollment US Study
NCT07405983Osteoarthritis Thumb, Thumb Carpometacarpal Joint Osteoarthritis
Keri Medical SA
Observational
163
Colorado, Indiana, North Carolina, Texas
2026-03-04
Recruiting
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
540
Alabama, Arizona, California, Georgia, Illinois, Indiana, Louisiana, Massachusetts
2026-03-03
Recruiting
Arcutis Biotherapeutics, Inc.
Phase 1
125
Florida, Indiana, New Jersey, Texas, Utah
2026-03-02
Recruiting
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
NCT07306559Advanced Relapsed or Refractory Germ Cell Tumours, Advanced Relapsed or Refractory Endometrial Cancer, Advanced Relapsed or Refractory Ovarian Cancer
Boehringer Ingelheim
Phase 1
187
California, Indiana, Texas
2026-02-27
Recruiting
Appello Pharmaceuticals, Inc.
Phase 2
150
Arkansas, California, Colorado, Florida, Georgia, Indiana, Kansas, Kentucky
2026-02-25
Recruiting
Novo Nordisk A/S
Phase 3
1,150
Florida, Georgia, Illinois, Indiana, Missouri, New York, North Carolina, Pennsylvania
2026-02-24
Recruiting
TearSolutions, Inc.
Phase 2
54
Florida, Indiana, Massachusetts, Minnesota, Missouri, New York
2026-02-19
Recruiting
Solventum US LLC
Not applicable
179
Indiana, Utah
2026-02-19
Active, closed
Ipsen
Phase 3
1,300
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana
2026-02-18
Recruiting
C4 Therapeutics, Inc.
Phase 2
100
Alabama, Arizona, California, Florida, Georgia, Indiana, Iowa, Michigan
2026-02-18
Recruiting
Amplified Sciences Inc
Observational
50
Indiana, Massachusetts, New Jersey
2026-02-17
Recruiting
Vanda Pharmaceuticals
Phase 3
300
Arizona, California, Florida, Indiana, New Hampshire, New York, North Carolina, Texas
2026-02-17
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
614
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Indiana, Kentucky
2026-02-17
Active, closed
EyePoint Pharmaceuticals, Inc.
Phase 3
240
California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana, Louisiana
2026-02-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
900
Alabama, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maine
2026-02-16
Recruiting
Aspiration Thrombectomy Using the Symphony or Prodigy System
NCT07350499Arterial Thromboembolism, Venous Thromboembolism, Pulmonary Embolism
Imperative Care, Inc.
Observational
750
Alabama, Florida, Illinois, Indiana, Michigan, New York, Ohio, Virginia
2026-02-13
Recruiting
Eli Lilly and Company
Phase 2
465
Arizona, Arkansas, California, Florida, Illinois, Indiana, Kentucky, Maryland
2026-02-13
Recruiting
Pfizer
Phase 2/3
1,156
Alabama, Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana
2026-02-11
Recruiting
Hoffmann-La Roche
Observational
2,000
California, Indiana, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Tennessee
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
1,000
California, Connecticut, Florida, Georgia, Indiana, Iowa, Maryland, Massachusetts
2026-02-09
Active, closed
EyePoint Pharmaceuticals, Inc.
Phase 3
240
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Kentucky
2026-02-09
Active, closed
Vaxcyte, Inc.
Phase 3
752
Arizona, Connecticut, Florida, Georgia, Indiana, Kansas, Louisiana, Maryland
2026-02-09
Recruiting
A Prospective, Post-Market, Clinical Follow-up Study of the Incompass™ Total Ankle System
NCT07118501Post Traumatic Arthritis, Osteoarthritis, Total Ankle Replacement, Total Ankle Prosthesis
Stryker Trauma and Extremities
Observational
200
Illinois, Indiana, Kentucky, Oregon, South Carolina
2026-02-06
Recruiting
C4 Therapeutics, Inc.
Phase 1
60
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2026-02-06
Recruiting
Corxel Pharmaceuticals
Phase 2
240
Alabama, California, Florida, Georgia, Illinois, Indiana, Maryland, Massachusetts
2026-02-06
Recruiting
Mannkind Corporation
Phase 2
100
California, Colorado, Connecticut, Florida, Indiana, Massachusetts, Oklahoma, Texas
2026-02-04
Recruiting
Exciva GmbH
Phase 2/3
300
California, Indiana, Mississippi, Missouri, New York, Ohio, Oregon, Vermont
2026-02-02
Recruiting
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
NCT06968845Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics
Phase 2
120
Alabama, California, Colorado, Connecticut, Florida, Indiana, Kansas, Michigan
2026-02-02
Recruiting
Corcept Therapeutics
Phase 2
80
Arizona, California, Florida, Georgia, Indiana, Kansas, Michigan, Minnesota
2026-01-27
By invitation
Immunovant Sciences GmbH
Phase 2
372
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Indiana
2026-01-26
Recruiting
Sanofi
Phase 3
751
Colorado, Florida, Illinois, Indiana, Louisiana, Missouri, New York, North Carolina
2026-01-22
Recruiting
CSL Behring
Phase 2
84
Arizona, California, Florida, Indiana, Louisiana, Maryland, Michigan, Minnesota
2026-01-22
Active, closed
Janssen Research & Development, LLC
Phase 2
189
California, Florida, Illinois, Indiana, Michigan, North Dakota, Oregon, Pennsylvania
2026-01-20
Recruiting
Sanofi
Phase 3
751
Arizona, California, Colorado, Florida, Indiana, Louisiana, Michigan, Missouri
2026-01-16
Recruiting
Janssen Research & Development, LLC
Phase 2
240
Arkansas, California, Florida, Georgia, Illinois, Indiana, New Mexico, North Carolina
2026-01-15
Recruiting
Renibus Therapeutics, Inc.
Phase 3
150
California, Colorado, Delaware, Florida, Georgia, Idaho, Illinois, Indiana
2026-01-13
Active, closed
Vaxcyte, Inc.
Phase 3
1,390
Arizona, Colorado, Florida, Indiana, Kansas, Kentucky, Michigan, Nebraska
2026-01-12
Recruiting
A Study of Buntanetap in Participants With PD
NCT07284784Parkinson's Disease (PD), Deep Brain Stimulation
DrugBuntanetap/posiphen
Annovis Bio Inc.
Phase 2/3
500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana
2026-01-09
Recruiting
Novo Nordisk A/S
Phase 3
460
California, Florida, Georgia, Idaho, Indiana, Kansas, Louisiana, Maryland
2026-01-08
Recruiting
AbbVie
Phase 2/3
680
Arizona, California, Colorado, Georgia, Indiana, Minnesota, New York, North Carolina
2026-01-08
By invitation
MDR Vivacit-E Elevated Study
NCT07150221Osteoarthritis (OA) of the Hip, Avascular Necrosis of Bone of Hip, Protrusio Acetabuli, Traumatic Arthropathy-Hip
Zimmer Biomet
Observational
52
Indiana
2026-01-07
By invitation
Medtronic
Observational
2,000
Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Indiana
2026-01-07
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Arizona, Arkansas, California, Florida, Illinois, Indiana, Louisiana, Maryland
2026-01-06
Recruiting
Disc Medicine, Inc
Phase 1
24
Alabama, California, Georgia, Illinois, Indiana, New York, North Carolina, Ohio
2026-01-06
Recruiting
Janssen Research & Development, LLC
Phase 3
115
California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana, Massachusetts
2026-01-05
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Iowa
2025-12-31
Recruiting
Complement Therapeutics
Phase 1/2
75
Indiana, Nevada, Texas, Wisconsin
2025-12-30
Recruiting
AstraZeneca
Phase 3
1,100
Alabama, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kentucky
2025-12-29
Active, closed
UCB Biopharma SRL
Phase 2
165
California, Florida, Georgia, Illinois, Indiana, Kentucky, Michigan, Nebraska
2025-12-29
Recruiting
Sanofi
Phase 2
144
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky
2025-12-29
Recruiting
Diagnosing Epilepsy To EffeCT Change
NCT07110337Epilepsy, Epilepsy (Treatment Refractory)
Epiminder America, Inc.
Not applicable
210
Alabama, Arizona, California, Connecticut, Florida, Indiana, Massachusetts, Michigan
2025-12-23
Recruiting
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
NCT07110454Epilepsy, Epilepsy (Treatment Refractory)
Epiminder America, Inc.
Observational
210
Alabama, Arizona, California, Connecticut, Florida, Indiana, Massachusetts, Minnesota
2025-12-23
Recruiting
DiscGenics, Inc.
Phase 3
162
Alabama, Arizona, California, District of Columbia, Florida, Idaho, Indiana, Kentucky
2025-12-23
Recruiting
Tyra Biosciences, Inc
Phase 2
230
California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri
2025-12-22
Recruiting
Enveda Therapeutics
Phase 2
105
Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky
2025-12-22
Recruiting
Children's Viewing Behavior
NCT07229365Myopia, Myopia Progression, Juvenile Myopia
SightGlass Vision, Inc.
Not applicable
20
Indiana
2025-12-22
Recruiting
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
NCT07246590Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Verrica Pharmaceuticals Inc.
Phase 3
300
Florida, Indiana, Maryland, Tennessee, Texas
2025-12-17
Recruiting
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
NCT07194070Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC
Observational
175
Indiana, New York, Ohio, Oregon, Texas
2025-12-17
Recruiting
Hummingbird Bioscience
Phase 1/2
180
California, Indiana, Michigan, Texas
2025-12-17
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 3
500
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-12-15
Recruiting
Eccogene
Phase 2
160
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Louisiana
2025-12-15
Recruiting
Angitia Incorporated Limited
Phase 2
80
Arizona, Connecticut, Delaware, Indiana, Missouri, New Mexico, Ohio, Oregon
2025-12-12
Recruiting
Medtronic Neurovascular Clinical Affairs
Observational
118
Florida, Georgia, Illinois, Indiana, Iowa, Michigan, Missouri, South Carolina
2025-12-12
Recruiting
SOFIE
Phase 3
200
California, Florida, Indiana, Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2025-12-11
Recruiting
AbbVie
Phase 2/3
490
Arkansas, California, Florida, Indiana, Minnesota, Nebraska, New Hampshire, New Jersey
2025-12-10
Recruiting
Boehringer Ingelheim
Phase 3
120
Alabama, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2025-12-09
Recruiting
Eli Lilly and Company
Phase 2
60
Arizona, California, Connecticut, Florida, Illinois, Indiana, Kentucky, Maryland
2025-12-08
Active, closed
Oruka Therapeutics, Inc.
Phase 2
160
Arizona, Arkansas, California, Florida, Illinois, Indiana, Maryland, New York
2025-12-03
Recruiting
Ventus Therapeutics U.S., Inc.
Phase 2
24
California, Florida, Indiana, Michigan, Missouri, New Mexico, New York, Tennessee
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 3
366
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Indiana
2025-12-03
Recruiting
Pfizer
Phase 3
500
Alabama, Arkansas, California, Florida, Idaho, Indiana, Missouri, South Carolina
2025-12-02
Active, closed
Vaxcyte, Inc.
Phase 3
4,049
Alabama, Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana
2025-12-01
Recruiting
Sun Pharmaceutical Industries, Inc.
Phase 3
260
Arizona, California, Colorado, Florida, Idaho, Illinois, Indiana, Minnesota
2025-11-29
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
California, Colorado, Florida, Georgia, Illinois, Indiana, Mississippi, New York
2025-11-28
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Alabama, Arizona, California, Florida, Indiana, Michigan, Minnesota, Nebraska
2025-11-27
By invitation
Soleno Therapeutics, Inc.
Observational
200
Arizona, California, Colorado, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-11-26
Recruiting
AbbVie
Phase 2
180
Connecticut, Florida, Indiana, Kentucky, Massachusetts, Michigan, Missouri, Ohio
2025-11-25
Recruiting
SAb Biotherapeutics, Inc.
Phase 2
159
California, Colorado, Florida, Georgia, Indiana, Massachusetts, Missouri, New Mexico
2025-11-25
Recruiting
Syndax Pharmaceuticals
Phase 3
468
Arizona, California, Indiana, Louisiana, Rhode Island, Texas
2025-11-25
By invitation
Celldex Therapeutics
Phase 3
1,370
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-11-25
Active, closed
Biohaven Therapeutics Ltd.
Phase 2
150
California, Florida, Illinois, Indiana, Louisiana, Missouri, North Carolina, North Dakota
2025-11-24
Recruiting
Regeneron Pharmaceuticals
Phase 3
2,000
California, Colorado, Florida, Illinois, Indiana, Kansas, Maryland, Massachusetts
2025-11-24
Recruiting
AbbVie
Phase 2
140
Alabama, California, Connecticut, Florida, Illinois, Indiana, Kentucky, Louisiana
2025-11-21
Recruiting
Sun Pharmaceutical Industries, Inc.
Phase 3
160
California, Florida, Illinois, Indiana, Minnesota, Missouri, Oregon, South Carolina
2025-11-19
Recruiting
Bayer
Phase 3
111
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2025-11-19
Recruiting
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
NCT07217704Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
Drug[18F]FAPI-74 PET/CT
SOFIE
Phase 3
200
California, Florida, Indiana, Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2025-11-14
Active, closed
Pfizer
Phase 2
128
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kansas
2025-11-13
Recruiting
Incyte Corporation
Phase 2
160
Alabama, California, District of Columbia, Florida, Georgia, Indiana, Iowa, Kentucky
2025-11-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
996
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas
2025-11-11
Recruiting
Eli Lilly and Company
Phase 2
252
Arizona, California, Colorado, Florida, Illinois, Indiana, Kentucky, Massachusetts
2025-11-10
Recruiting
Feeltect Limited
Not applicable
40
Indiana
2025-11-06
Active, closed
Novo Nordisk A/S
Phase 3
300
California, Colorado, Florida, Illinois, Indiana, Missouri, North Carolina, Virginia
2025-11-05
Recruiting
AbbVie
Phase 3
561
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa
2025-11-05
Active, closed
Novo Nordisk A/S
Phase 3
330
Alabama, Arizona, California, Florida, Hawaii, Indiana, Nevada, New York
2025-11-05
Recruiting
Incyte Corporation
Phase 1
24
Arizona, California, Colorado, Florida, Georgia, Indiana, Kentucky, Louisiana
2025-11-03
Active, closed
Bluefin Biomedicine, Inc.
Phase 2/3
210
Arizona, California, Florida, Georgia, Indiana, Kentucky, Louisiana, Michigan
2025-11-03
Recruiting
Eli Lilly and Company
Phase 3
1,205
Alabama, Arizona, California, Colorado, Florida, Indiana, Maryland, Michigan
2025-10-31
Recruiting
Retension Pharmaceuticals. Inc.
Phase 2
280
Alabama, Arizona, California, Connecticut, Florida, Georgia, Indiana, Louisiana
2025-10-31
Recruiting
GlaxoSmithKline
Phase 2
363
Alabama, Arizona, California, Colorado, Florida, Indiana, Louisiana, Maryland
2025-10-30
Recruiting
AstraZeneca
Phase 3
100
Florida, Indiana, Nebraska, New York, Texas, Washington
2025-10-30
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
DrugAvacincaptad Pegol
ONL Therapeutics
Phase 2
324
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2025-10-28
Recruiting
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
NCT07211178Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer
Tempus AI
Observational
900
Alabama, California, Florida, Illinois, Indiana, Michigan, Missouri, Nevada
2025-10-27
Recruiting
Novo Nordisk A/S
Phase 1
30
Colorado, Indiana, Iowa, Pennsylvania
2025-10-23
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
Eli Lilly and Company
Phase 1
241
California, Florida, Indiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2025-10-22
Recruiting
Ankyra Therapeutics, Inc
Phase 1
60
Florida, Illinois, Indiana, Michigan, Minnesota, New York, North Carolina, Pennsylvania
2025-10-22
Recruiting
Virtue® SAB in the Treatment of Coronary ISR Trial
NCT07045194Coronary Artery Disease
Orchestra BioMed, Inc
Not applicable
740
Florida, Indiana, Kansas, Maryland, Michigan, New York, North Carolina, Ohio
2025-10-20
Active, closed
Galderma R&D
Phase 2
50
Alabama, Arizona, California, Florida, Indiana, Kentucky, Maryland, Michigan
2025-10-20
Recruiting
Regeneron Pharmaceuticals
Phase 2
1,200
Alabama, California, Florida, Georgia, Indiana, Louisiana, Maryland, Massachusetts
2025-10-20
Recruiting
Nurix Therapeutics, Inc.
Phase 2
100
Arizona, California, Colorado, Florida, Indiana, Iowa, Maryland, Michigan
2025-10-15
Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
NCT07174583Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3
DrugsDurvalumab·Carboplatin
IDEAYA Biosciences
Phase 1/2
262
Colorado, Florida, Indiana, Michigan, New York, Pennsylvania, Tennessee, Texas
2025-10-14
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Alabama, Connecticut, Florida, Georgia, Indiana, Maine, New Jersey, New York
2025-10-08
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-03
Recruiting
Luminate Medical, Inc.
Not applicable
142
California, Connecticut, Florida, Hawaii, Illinois, Indiana, Minnesota, New Jersey
2025-10-03
Recruiting
Janssen Research & Development, LLC
Phase 3
882
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-01
Recruiting
Price Vision Group
Phase 2/3
500
Indiana
2025-10-01
Recruiting
Urotronic Inc.
Not applicable
60
California, Florida, Indiana, New York, Texas, Utah
2025-10-01
Recruiting
Daiichi Sankyo
Phase 3
710
Florida, Indiana, Louisiana, North Carolina, Ohio, South Dakota, Texas
2025-09-30
Recruiting
Clinical Course Of Disease In Participants With FA-CM
NCT06865482Friedreich Ataxia, Cardiomyopathy
Lexeo Therapeutics
Observational
65
California, Florida, Indiana, Massachusetts, Minnesota, Missouri, Ohio, Oregon
2025-09-30
Active, closed
Incisive Technologies Pty Ltd
Not applicable
12
Indiana
2025-09-24
Recruiting
Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome
NCT06776783Respiratory Distress Syndrome, Pre-term Infants
Aerogen Pharma Limited
Phase 3
520
Arkansas, California, Florida, Indiana, New Jersey, New York, Texas, Virginia
2025-09-24
Recruiting
Sanofi
Phase 4
35
California, Indiana, Iowa, Ohio
2025-09-23
Recruiting
W.L.Gore & Associates
Not applicable
112
Alabama, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-09-22
Recruiting
Sanofi
Phase 3
942
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Louisiana
2025-09-16
Recruiting
AMEND TS Early Feasibility Study
NCT06951672Symptomatic Functional MR 3 or Greater
Valcare Medical Ltd.
Not applicable
15
Arizona, California, Georgia, Indiana, New York, Oregon, Tennessee, Texas
2025-09-11
Recruiting
Janssen Research & Development, LLC
Phase 3
220
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana
2025-09-10
Recruiting
Pfizer
Phase 3
140
California, Florida, Indiana, Maryland, Michigan, Nebraska, New Mexico, New York
2025-09-10
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
NCT06689839Aortic Stenosis Treated With TAVI, Aortic Diseases
EnCompass Technologies, Inc.
Not applicable
500
Florida, Indiana, Michigan, Missouri, New York, Ohio, Virginia
2025-09-09
Recruiting
Neuspera Medical, Inc.
Not applicable
116
California, Florida, Indiana, Kansas, Kentucky, Louisiana, Michigan, Minnesota
2025-09-03
Active, closed
Triveni Bio
Phase 2
95
California, Florida, Indiana, Pennsylvania, Texas, Washington
2025-08-26
Recruiting
Climb Bio, Inc.
Phase 2
45
Colorado, Florida, Georgia, Indiana, New York, Texas
2025-08-25
Recruiting
PSMA PET Combined With MRI for the Detection of PCa
NCT07052214PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET
DrugIlluccix
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
338
California, Florida, Illinois, Indiana, Louisiana, Missouri, New York, Pennsylvania
2025-08-18
Recruiting
HCW Biologics
Phase 1
30
Florida, Indiana, Ohio
2025-08-16
Recruiting
Takeda
Phase 3
150
Arkansas, California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky
2025-08-14
Recruiting
Abbott Cephea Mitral Valve Disease Registry
NCT07069673Mitral Regurgitation, Mitral Stenosis, Mitral Valve Disease, Mitral Valve (MV) Regurgitation
Abbott Medical Devices
Observational
1,000
Alabama, Arizona, California, Georgia, Illinois, Indiana, Kansas, Minnesota
2025-08-13
Recruiting
AbbVie
Phase 1/2
66
Indiana, Nevada, Texas
2025-08-13
Recruiting
Sanofi
Phase 3
192
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2025-08-12
Recruiting
Galderma R&D
Observational
600
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2025-08-11
Recruiting
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
NCT06927739Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease
Abcentra
Phase 2
240
California, Florida, Indiana, Kentucky, Maryland, Michigan
2025-08-11
Active, closed
Novo Nordisk A/S
Phase 3
877
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-08-11
Recruiting
AstraZeneca
Phase 3
700
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Maryland
2025-08-06
Recruiting
Zydus Therapeutics Inc.
Phase 1
6
Indiana
2025-08-05
Recruiting
Crystalys Therapeutics
Phase 3
250
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-08-04
Recruiting
Crystalys Therapeutics
Phase 3
500
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-08-01
Recruiting
AstraZeneca
Phase 3
800
Arizona, California, District of Columbia, Florida, Hawaii, Illinois, Indiana, Maine
2025-08-01
Recruiting
Scalable Intervention for Stress Management
NCT07127575Stress, Diaphragmatic Breathing
Livotion, LLC
Not applicable
60
Indiana
2025-08-01
Active, closed
Pfizer
Phase 3
208
California, Colorado, District of Columbia, Florida, Illinois, Indiana, Maryland, Michigan
2025-07-31
Recruiting
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
NCT07144137Geographic Atrophy Secondary to Age-related Macular Degeneration
Complement Therapeutics
Observational
75
California, Illinois, Indiana, Nevada, North Carolina, Pennsylvania, Texas, Wisconsin
2025-07-30
Recruiting
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
NCT07024693Fuchs Endothelial Corneal Dystrophy, Fuchs
Design Therapeutics, Inc.
Phase 2
70
Indiana, Michigan
2025-07-30
Recruiting
Study of BHV-1400 in IgA Nephropathy
NCT07054684IgA Nephropathy
Biohaven Therapeutics Ltd.
Phase 1
20
Connecticut, Florida, Georgia, Illinois, Indiana, Michigan, Missouri, South Dakota
2025-07-30
Recruiting
Kodiak Sciences Inc
Phase 3
600
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2025-07-30
Recruiting
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
DrugsCisplatin·Carboplatin·Pembrolizumab
Eli Lilly and Company
Phase 1
240
California, Florida, Illinois, Indiana, Massachusetts, Missouri, New Jersey, New York
2025-07-28
Recruiting
Kiniksa Pharmaceuticals International, plc
Phase 2/3
325
Arizona, California, Colorado, District of Columbia, Georgia, Illinois, Indiana, Kansas
2025-07-25
Recruiting
Pfizer
Phase 3
150
Alabama, Arkansas, California, Florida, Idaho, Indiana, Missouri, South Carolina
2025-07-24
Recruiting
Tempus AI
Not applicable
900
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana
2025-07-23
Recruiting
4D Molecular Therapeutics
Phase 3
480
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Maryland
2025-07-22
Recruiting
Bristol-Myers Squibb
Phase 3
586
California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan, Mississippi
2025-07-21
Recruiting
Kodiak Sciences Inc
Phase 3
300
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2025-07-16
Active, closed
Bluefin Biomedicine, Inc.
Phase 2
225
Arizona, California, Florida, Georgia, Indiana, Louisiana, Massachusetts, Michigan
2025-07-15
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Arizona, California, Colorado, Florida, Georgia, Indiana, Louisiana, Massachusetts
2025-07-14
Recruiting
Galderma R&D
Observational
1,000
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2025-07-14
Recruiting
Krystal Biotech, Inc.
Phase 1/2
60
California, Indiana, Minnesota, Missouri, New Jersey, North Dakota, Pennsylvania
2025-07-07
Active, closed
Novartis Pharmaceuticals
Phase 2
138
California, Colorado, Connecticut, Indiana, Massachusetts, Nebraska, New York, Pennsylvania
2025-07-03
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana
2025-07-02
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
2,400
Arizona, California, Colorado, Florida, Georgia, Indiana, Louisiana, Maine
2025-06-30
Active, closed
Stone and Laser Therapies Post-Market Study (SALT)
NCT06982235Benign Prostate Hypertrophy(BPH), Renal Calculi, Ureteral Stones, Kidney Stones, Calculi, Urinary
Boston Scientific Corporation
Observational
238
Arizona, Florida, Indiana, North Carolina
2025-06-30
By invitation
MoonLake Immunotherapeutics AG
Phase 3
835
Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky
2025-06-27
Recruiting
Vektor Medical
Not applicable
423
Arkansas, Florida, Georgia, Indiana, Kentucky, New York, Ohio, Pennsylvania
2025-06-27
Recruiting
Kardigan, Inc.
Phase 2/3
1,276
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2025-06-27
Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06995677Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration
DrugTYRA-300
Tyra Biosciences, Inc
Phase 2
90
Alabama, Arkansas, California, Illinois, Indiana, Kansas, Maryland, Massachusetts
2025-06-27
Recruiting
Eli Lilly and Company
Phase 3
290
Alabama, California, Florida, Idaho, Illinois, Indiana, Kentucky, Louisiana
2025-06-26
By invitation
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
NCT07008469Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia
Avidity Biosciences, Inc.
Phase 3
199
California, Colorado, Florida, Indiana, Kansas, Maryland, Massachusetts, Minnesota
2025-06-26
Recruiting
Eli Lilly and Company
Phase 3
350
Alabama, California, Florida, Idaho, Illinois, Indiana, Kentucky, Louisiana
2025-06-26
Active, closed
Incyte Corporation
Phase 3
580
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-06-23
Recruiting
Lactea Therapeutics, LLC
Not applicable
32
Indiana
2025-06-23
Recruiting
Enterra Medical, Inc.
Not applicable
148
Arizona, California, Florida, Illinois, Indiana, Kentucky, New Jersey, Ohio
2025-06-23
Recruiting
Apellis Pharmaceuticals, Inc.
Phase 2
240
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2025-06-23
Recruiting
Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
NCT06658730Vascular Disease, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta
W.L.Gore & Associates
Observational
1,500
Arizona, California, District of Columbia, Florida, Georgia, Indiana, Maryland, Massachusetts
2025-06-19
Recruiting
Pfizer
Phase 2
620
California, Florida, Illinois, Indiana, Maryland, Nebraska, Ohio, Texas
2025-06-19
Recruiting
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
NCT06608823Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency
JenaValve Technology, Inc.
Not applicable
1,016
California, District of Columbia, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-06-18
Active, closed
AbbVie
Phase 3
573
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2025-06-17
Active, closed
Altimmune, Inc.
Phase 2
121
Arizona, Arkansas, California, Florida, Georgia, Indiana, Kentucky, Louisiana
2025-06-16
Active, closed
Eli Lilly and Company
Phase 4
233
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2025-06-16
Recruiting
Relay Therapeutics, Inc.
Phase 2
277
Arizona, Arkansas, California, Colorado, Georgia, Indiana, Iowa, Maryland
2025-06-13
Active, closed
Merck Sharp & Dohme LLC
Phase 2
149
Alabama, Arizona, Arkansas, California, Florida, Georgia, Indiana, Massachusetts
2025-06-09
Recruiting
Boehringer Ingelheim
Phase 2
300
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-06-05
By invitation
Virtuos Bone Graft in Lumbar Fusion
NCT06686017Degenerative Disc Disease
Orthofix Inc.
Observational
150
Indiana, Michigan, Montana, North Carolina, South Carolina, Texas, Virginia
2025-06-05
Active, closed
Novo Nordisk A/S
Phase 3
609
California, Florida, Georgia, Illinois, Indiana, Iowa, Michigan, Missouri
2025-06-03
Recruiting
Tango Therapeutics, Inc.
Phase 1/2
183
Arizona, Colorado, District of Columbia, Florida, Illinois, Indiana, Iowa, Massachusetts
2025-05-31
Active, closed
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07011706Atopic Dermatitis, Atopic, Dermatitis, AD
Aclaris Therapeutics, Inc.
Phase 2
110
Arizona, Arkansas, California, Florida, Georgia, Idaho, Indiana, Kentucky
2025-05-30
Active, closed
Arvinas Inc.
Phase 1/2
76
Arizona, Connecticut, Florida, Indiana, Michigan, New York, North Carolina, Ohio
2025-05-29
Active, closed
AstraZeneca
Phase 3
3,103
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2025-05-28
Active, closed
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
NCT06931405Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Blueprint Medicines Corporation
Phase 2
105
Alabama, Arkansas, California, Florida, Idaho, Illinois, Indiana, Kentucky
2025-05-28
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Alabama, California, Connecticut, District of Columbia, Georgia, Illinois, Indiana, Iowa
2025-05-22
Recruiting
Minima Stent System Post- Approval Study (PAS)
NCT06828770Pulmonary Artery Stenosis, Aortic Coarctation
Renata Medical
Observational
100
California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-05-21
Recruiting
Boehringer Ingelheim
Phase 3
4,200
California, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Louisiana
2025-05-20
Active, closed
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT06970847Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant
Drug64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Phase 3
220
California, Florida, Illinois, Indiana, Louisiana, Minnesota, Missouri, Nebraska
2025-05-16
Active, closed
Zura Bio Inc
Phase 2
225
Arizona, California, Florida, Georgia, Indiana, Kentucky, Louisiana, Massachusetts
2025-05-16
Active, closed
An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure
NCT06859970Heart Failure, Heart Failure NYHA Class III, Heart Failure With Reduced Ejection Fraction, Ambulatory Heart Failure, NYHA Class IV
InterShunt Technologies, Inc.
Not applicable
20
Arkansas, California, Indiana, Ohio, Texas
2025-05-15
Recruiting
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
NCT06783309Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus
COUR Pharmaceutical Development Company, Inc.
Phase 1/2
72
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-05-12
Active, closed
Werewolf Therapeutics, Inc.
Phase 1/2
100
Arizona, Georgia, Illinois, Indiana, Texas
2025-05-07
Recruiting
Pfizer
Phase 4
100
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Kentucky
2025-05-07
Active, closed
Novartis Pharmaceuticals
Phase 3
246
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2025-04-30
Active, closed
Procter and Gamble
Phase 1
135
Indiana
2025-04-30
Recruiting
Pacific Edge Limited
Not applicable
1,000
Alabama, California, Florida, Indiana, Louisiana, Maryland, New Jersey, New York
2025-04-29
Active, closed
Eli Lilly and Company
Phase 3
905
California, Colorado, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa
2025-04-25
Recruiting
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
NCT06414460Locally Advanced/Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1/2
146
Colorado, Connecticut, Indiana, Tennessee, Texas
2025-04-25
Recruiting
Arrowhead Pharmaceuticals
Phase 3
288
California, Connecticut, Illinois, Indiana, Kansas, Michigan, Missouri, Nebraska
2025-04-24
Recruiting
Evaluating Therapeutic Electrical Stimulation to Improve Nerve Healing After Surgical Repair of Digital Nerve Injuries
NCT06867185Digital Nerve Injury, Nerve Injury, Nerve Reconstruction, Nerve Trauma
Checkpoint Surgical Inc.
Not applicable
60
Indiana, Missouri, Ohio, Washington
2025-04-24
Active, closed
Pivotal Study of Voro Urologic Scaffold
NCT06873581Radical Prostatectomy, Stress Urinary Incontinence (SUI)
Levee Medical, Inc.
Phase 3
266
Arizona, California, Florida, Illinois, Indiana, Maryland, Mississippi, New York
2025-04-18
Active, closed
Janssen Research & Development, LLC
Phase 3
752
Alabama, California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa
2025-04-15
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Alabama, Alaska, California, Connecticut, Florida, Georgia, Indiana, Kansas
2025-04-09
Active, closed
Arrowhead Pharmaceuticals
Phase 3
710
California, Florida, Georgia, Illinois, Indiana, Kansas, Maryland, Michigan
2025-04-09
Recruiting
Gilead Sciences
Phase 3
695
Alaska, Arkansas, California, Florida, Illinois, Indiana, Kentucky, Maine
2025-04-04
Recruiting
Corza Medical GmbH
Phase 3
116
California, Colorado, District of Columbia, Illinois, Indiana, Kentucky, Missouri, North Carolina
2025-04-02
Recruiting
Incyte Corporation
Phase 3
572
California, Florida, Georgia, Indiana, Kansas, Massachusetts, Michigan, Missouri
2025-04-02
Active, closed
Hoffmann-La Roche
Phase 2
162
California, Florida, Georgia, Indiana, Michigan, Minnesota, New Jersey, New York
2025-04-01
Recruiting
Pfizer
Phase 3
674
Alabama, Arkansas, California, Connecticut, Florida, Illinois, Indiana, Iowa
2025-04-01
Recruiting
Eli Lilly and Company
Phase 2
200
Arizona, California, Florida, Georgia, Idaho, Indiana, New Jersey, New York
2025-03-28
Recruiting
The Pivotal Study of RapidPulseTM Aspiration System
NCT06029491Acute Ischemic Stroke
RapidPulse, Inc
Not applicable
170
California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Missouri
2025-03-27
Active, closed
Novartis Pharmaceuticals
Phase 2
396
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-03-26
Recruiting
AstraZeneca
Phase 2
540
California, Delaware, Florida, Idaho, Indiana, Iowa, Kansas, Kentucky
2025-03-26
Recruiting
Aldena Therapeutics
Phase 1/2
24
California, Indiana, Massachusetts, Washington
2025-03-24
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
206
California, Colorado, Florida, Georgia, Indiana, Michigan, Nebraska, New York
2025-03-21
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts
2025-03-20
Active, closed
TrueBinding, Inc.
Phase 2
62
California, Colorado, Florida, Illinois, Indiana, Kansas, Michigan, New York
2025-03-20
Recruiting
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Indiana, Kentucky, Maryland, Massachusetts
2025-03-19
Recruiting
Daiichi Sankyo
Phase 3
582
California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland, Massachusetts
2025-03-19
Recruiting
AstraZeneca
Phase 3
990
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-03-18
Active, closed
Amgen
Phase 3
1,105
Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Iowa
2025-03-17
Recruiting
BioPoly® Partial Resurfacing Knee Implant IDE
NCT06915363Knee Pain Chronic, Knee Osteoarthritis, Cartilage Damage, Cartilage Defects of the Knee
BioPoly LLC
Not applicable
152
Indiana, Minnesota, Missouri
2025-03-17
Active, closed
Novartis Pharmaceuticals
Phase 3
196
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-03-13
Recruiting
Bristol-Myers Squibb
Phase 3
60
California, Illinois, Indiana, New York, Ohio, Texas
2025-03-13
Active, closed
Safety and Efficacy of VDPHL01 in Males With AGA
NCT06972264Androgenetic Alopecia, AGA, Male Pattern Baldness
DrugVDPHL01
Veradermics, Inc.
Phase 3
480
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas
2025-03-11
Recruiting
Pfizer
Phase 3
723
Arizona, California, Florida, Georgia, Idaho, Indiana, Michigan, Missouri
2025-03-11
Recruiting
AbbVie
Phase 1/2
252
Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas, Massachusetts
2025-03-06
Active, closed
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2025-03-06
Recruiting
BeOne Medicines
Phase 3
300
Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Iowa
2025-03-05
Recruiting
Vanda Pharmaceuticals
Phase 3
500
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-03-03
Recruiting
Incyte Corporation
Phase 3
600
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Louisiana
2025-02-28
Recruiting
Summit Therapeutics
Phase 3
780
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-02-27
Recruiting
Takeda
Phase 3
171
Arkansas, California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky
2025-02-27
Recruiting
Novartis Pharmaceuticals
Phase 2/3
443
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2025-02-27
Recruiting
Hansoh BioMedical R&D Company
Phase 1
475
Florida, Indiana, North Carolina, Texas, Virginia
2025-02-26
Recruiting
Sitryx Therapeutics Ltd
Phase 1
149
Arkansas, California, Indiana, Ohio, Pennsylvania, Utah
2025-02-26
Recruiting
VIVEX Biologics, Inc.
Not applicable
325
California, Colorado, Florida, Georgia, Indiana, Kansas, Kentucky, Louisiana
2025-02-17
Recruiting
AbbVie
Phase 3
420
Alabama, Arkansas, California, Florida, Indiana, Michigan, Mississippi, Nebraska
2025-02-13
Recruiting
ConvaTec Inc.
Not applicable
235
California, Florida, Indiana, Maryland, Massachusetts, New York, North Carolina, Pennsylvania
2025-02-12
Active, closed
Sanofi
Phase 3
231
California, Florida, Georgia, Idaho, Illinois, Indiana, Missouri, New York
2025-02-12
Recruiting
Janssen Research & Development, LLC
Phase 3
50
Alabama, California, Colorado, Illinois, Indiana, Iowa, New York, North Carolina
2025-02-10
Recruiting
Healx Limited
Phase 2
25
Alabama, California, Colorado, District of Columbia, Illinois, Indiana, Maryland, Missouri
2025-02-10
Recruiting
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
NCT06785636mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer
Pathos AI, Inc.
Phase 1/2
120
California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2025-02-07
Recruiting
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
NCT06754852Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Hemab ApS
Phase 1/2
108
Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Michigan
2025-02-06
Recruiting
Medtronic Cardiovascular
Observational
225
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Indiana
2025-02-06
Recruiting
LEO Pharma
Phase 3
90
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-02-05
Recruiting
BioNTech SE
Phase 3
621
Arizona, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana
2025-02-03
Recruiting
Integrity Implant System Post Market Clinical Follow-Up Study
NCT06741527Rotator Cuff Tears of the Shoulder
Anika Therapeutics, Inc.
Not applicable
150
Arizona, California, Florida, Georgia, Indiana, Maryland, New Jersey, South Carolina
2025-02-01
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2025-01-31
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,046
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-01-27
Recruiting
BeOne Medicines
Phase 1/2
258
Florida, Indiana, Kansas, Massachusetts, Missouri, Washington
2025-01-23
Recruiting
Solventum US LLC
Not applicable
90
Indiana, Missouri, Pennsylvania
2025-01-20
Active, closed
argenx
Phase 3
631
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-01-15
Recruiting
Takeda
Phase 4
78
Alabama, Arizona, California, Delaware, Florida, Georgia, Illinois, Indiana
2025-01-14
Recruiting
PerQdisc Traditional Feasibility Trial.
NCT06860867Discogenic Low Back Pain
Spinal Stabilization Technologies
Not applicable
5
Arizona, Idaho, Indiana, Louisiana, Oklahoma
2025-01-10
Recruiting
GlaxoSmithKline
Phase 3
1,840
Alabama, Arkansas, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-01-10
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Alabama, Arizona, Arkansas, California, Florida, Illinois, Indiana, Kentucky
2025-01-08
Recruiting
BioNTech SE
Phase 2/3
1,580
Alabama, Alaska, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-01-07
Recruiting
Regeneron Pharmaceuticals
Phase 3
369
Arizona, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kentucky
2025-01-02
Recruiting
Takeda
Phase 3
396
California, Colorado, Florida, Indiana, Kentucky, New York, South Carolina, South Dakota
2025-01-02
By invitation
The ION Facet Screw System Ambispective Evaluation
NCT06720948Intra-facet ION 3D Facet Screw System
SurGenTec LLC
Observational
50
Indiana, Oklahoma, Texas
2025-01-01
Active, closed
MoonLake Immunotherapeutics AG
Phase 3
35
Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Kentucky
2024-12-30
Active, closed
argenx
Phase 3
154
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana
2024-12-18
Recruiting
Immunovant Sciences GmbH
Phase 2
240
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Indiana
2024-12-17
Active, closed
Radiopharm Theranostics, Ltd
Phase 2
30
Illinois, Indiana, Michigan
2024-12-13
Active, closed
Arcus Biosciences, Inc.
Phase 3
610
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-12-13
Recruiting
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
NCT06526195Heart Failure, Heart Diseases, Cardiovascular Diseases, Pulmonary Hypertension
Abbott Medical Devices
Not applicable
850
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2024-12-13
Recruiting
Study of GalaFLEX LITE™ Scaffold in Treatment of Capsular Contracture After Breast Implant Augmentation
NCT05945329Capsular Contracture Associated With Breast Implant, Capsular Contracture Grade III, Capsular Contracture Grade IV
C. R. Bard
Not applicable
250
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana
2024-12-12
Recruiting
Basilea Pharmaceutica
Phase 3
450
Alabama, California, Georgia, Indiana, Kentucky, Maryland, Michigan, Minnesota
2024-12-11
Active, closed
Hoffmann-La Roche
Phase 3
350
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-12-11
Active, closed
Amgen
Phase 3
707
Alabama, California, Florida, Illinois, Indiana, Kentucky, Massachusetts, Michigan
2024-12-09
Recruiting
Intra-Cellular Therapies, Inc.
Phase 3
160
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Indiana, Louisiana
2024-12-06
By invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugVutrisiran
Alnylam Pharmaceuticals
Phase 3
700
Arizona, California, District of Columbia, Illinois, Indiana, Kansas, Maryland, Massachusetts
2024-12-03
Active, closed
H. Lundbeck A/S
Phase 3
401
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Indiana, Maryland
2024-12-03
Recruiting
Novo Nordisk A/S
Phase 2
465
California, Colorado, Florida, Illinois, Indiana, Michigan, Missouri, New York
2024-12-02
Active, closed
Ocular Therapeutix, Inc.
Phase 3
825
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-11-27
Active, closed
EyePoint Pharmaceuticals, Inc.
Phase 3
400
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Kentucky
2024-11-27
Active, closed
CereVasc Inc
Not applicable
230
California, Connecticut, Florida, Illinois, Indiana, Kansas, Kentucky, Massachusetts
2024-11-26
Active, closed
Genmab
Phase 3
191
Arizona, California, Florida, Georgia, Hawaii, Illinois, Indiana, Kentucky
2024-11-25
Active, closed
BioMarin Pharmaceutical
Phase 2
30
California, Colorado, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana
2024-11-22
Recruiting
UCB Biopharma SRL
Phase 3
450
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-11-21
Recruiting
InspireMD
Not applicable
50
California, Indiana, Minnesota, Missouri, Montana, New York, Ohio
2024-11-20
Recruiting
Eli Lilly and Company
Phase 3
125
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-11-18
Active, closed
Evaluation of a Simple-Prep Controlled Embolic
NCT06453642Embolization, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma
Fluidx Medical Technology, Inc.
Not applicable
114
California, Colorado, Illinois, Indiana, Minnesota, Missouri, New York, North Carolina
2024-11-18
Recruiting
Day One Biopharmaceuticals, Inc.
Phase 1
300
Connecticut, Florida, Indiana, Michigan, New York, Oklahoma, Tennessee, Texas
2024-11-18
Recruiting
AvertD Post-Approval Study
NCT07135323Opioid Use Disorder
Prescient Medicine Holdings, Inc.
Observational
4,000
Indiana
2024-11-15
Recruiting
Bone Mineral Density Precision Study
NCT06830811Indicated for EOSedge Imaging
Alphatec Spine, Inc.
Not applicable
30
Indiana
2024-11-13
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Iowa
2024-11-12
Recruiting
LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)
NCT06462729Degenerative Disc Disease, Lumbar Disc Disease, Spine Disease, Lumbar Spine Degeneration
Locate Bio Pty Ltd
Phase 1/2
40
Indiana, North Carolina, Tennessee
2024-11-12
Active, closed
AbbVie
Phase 2
74
California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana
2024-11-08
Active, closed
Alnylam Pharmaceuticals
Phase 1/2
89
Alabama, California, Florida, Indiana, Massachusetts, Minnesota, Missouri, North Carolina
2024-11-07
Recruiting
Takeda
Phase 3
24
Alabama, Florida, Illinois, Indiana, Iowa, Michigan, Minnesota, Nevada
2024-11-06
Not yet open
Nasotrak Medical Pte Ltd
Not applicable
90
Indiana, New York
2024-11-01
Active, closed
Dren Bio
Phase 1
81
California, Florida, Georgia, Idaho, Indiana, Massachusetts, Michigan, Pennsylvania
2024-10-30
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
196
Georgia, Indiana, Ohio, Texas, Utah
2024-10-29
Recruiting
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT06625775Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors
DrugsBBO-10203·Ribociclib·Folfox·Fulvestrant
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
392
California, Florida, Indiana, Massachusetts, Missouri, New York, Tennessee, Texas
2024-10-29
Recruiting
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
NCT06310031Cardiovascular Diseases, Heart Diseases, Heart Failure
BrioHealth Solutions, Inc.
Not applicable
780
Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kansas
2024-10-28
Recruiting
Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients
NCT06049680Malnutrition, Child, Malnutrition, Essential Fatty Acid Deficiency (EFAD), Parenteral Nutrition Associated Cholestasis
DrugSMOFlipid
Fresenius Kabi
Phase 4
100
Georgia, Illinois, Indiana, Ohio, Pennsylvania
2024-10-28
Active, closed
Eli Lilly and Company
Phase 2
45
California, Indiana, Maryland, Michigan, Minnesota, Rhode Island, Texas
2024-10-25
Active, closed
Amgen
Phase 3
19
Georgia, Indiana, Minnesota, New York, North Carolina, Ohio, Pennsylvania, Texas
2024-10-22
Active, closed
Esprit BTK Post-Approval Study
NCT06656364Chronic Limb-Threatening Ischemia
Abbott Medical Devices
Not applicable
200
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2024-10-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana
2024-10-21
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Cetuximab·Irinotecan
Eli Lilly and Company
Phase 1
750
Alabama, Arizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan
2024-10-21
Recruiting
Thrombolex, Inc.
Not applicable
500
Arizona, Florida, Georgia, Illinois, Indiana, Massachusetts, Mississippi, New Hampshire
2024-10-17
Recruiting
Proniras Corporation
Phase 1
40
Indiana
2024-10-16
Recruiting
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
NCT06663319Colorectal Neoplasms, Gastrointestinal Neoplasms
DrugsFolfox·Bevacizumab
Janssen Research & Development, LLC
Phase 1
260
Arizona, Colorado, Florida, Indiana, Michigan, Washington
2024-10-15
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana
2024-10-14
Recruiting
Boehringer Ingelheim
Phase 2
588
Alaska, Arizona, California, Connecticut, Florida, Illinois, Indiana, Maryland
2024-10-11
Active, closed
Incyte Corporation
Phase 3
349
Alabama, Arizona, Arkansas, California, Florida, Illinois, Indiana, Michigan
2024-10-10
Recruiting
Kyowa Kirin Co., Ltd.
Phase 1/2
39
California, Connecticut, Indiana, Minnesota, Tennessee
2024-10-09
Recruiting
Post-Market Clinical Investigation of the IotaSOFT Insertion System
NCT06664697Hearing Loss, Cochlear, Cochlear Implantation, Hearing Loss, Sensorineural
iotaMotion, Inc.
Observational
50
Indiana, Iowa, Oregon
2024-10-01
Recruiting
GlaxoSmithKline
Phase 1
845
California, Colorado, Connecticut, Indiana, Massachusetts, Michigan, New Jersey, South Carolina
2024-09-30
Recruiting
Registry for Stage 2 Type 1 Diabetes
NCT06481904Type 1 Diabetes
DrugTzield
Sanofi
Observational
200
California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2024-09-27
Recruiting
GlaxoSmithKline
Phase 2
393
Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana, Michigan
2024-09-27
Recruiting
BioCryst Pharmaceuticals
Phase 1
78
California, Connecticut, Illinois, Indiana
2024-09-26
Recruiting
Pfizer
Phase 2
48
California, Colorado, Indiana, Kentucky, Massachusetts, North Carolina, Texas
2024-09-25
Recruiting
Catalyst Pharmaceuticals, Inc.
Observational
250
Arizona, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kansas
2024-09-25
Active, closed
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
DrugSotagliflozin
Lexicon Pharmaceuticals
Phase 3
500
Arizona, California, Florida, Georgia, Illinois, Indiana, Maryland, Massachusetts
2024-09-24
Recruiting
Janssen Research & Development, LLC
Phase 2/3
274
Arizona, California, Florida, Georgia, Illinois, Indiana, Maine, Maryland
2024-09-19
Active, closed
Safety and Effectiveness of Cochlear Implantation in an Expanded Adult Population
NCT06293482Hearing Loss, Sensorineural, Hearing Loss, Bilateral
Cochlear
Not applicable
50
Arizona, California, Florida, Indiana, Missouri, New York, Ohio, Pennsylvania
2024-09-17
Active, closed
Novo Nordisk A/S
Phase 4
500
California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Louisiana
2024-09-17
Active, closed
Hoffmann-La Roche
Phase 3
400
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2024-09-17
Recruiting
A Study of VET3-TGI in Patients With Solid Tumors
NCT06444815Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer
DrugAtezolizumab
KaliVir Immunotherapeutics
Phase 1
60
California, Florida, Indiana, Pennsylvania, Texas
2024-09-16
Recruiting
CG Oncology, Inc.
Phase 2
325
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-09-16
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Cetuximab·Irinotecan·Adrucil
Eli Lilly and Company
Phase 1
630
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-09-12
Active, closed
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Priovant Therapeutics, Inc.
Phase 3
371
Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas, Maryland
2024-09-11
Recruiting
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
NCT06559150Non-cystic Fibrosis Bronchiectasis
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Phase 2
284
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Indiana, Iowa
2024-09-11
Recruiting
Abbott Medical Devices
Not applicable
100
Alabama, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Minnesota
2024-09-11
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
130
Arizona, California, Colorado, Connecticut, Florida, Indiana, Louisiana, Michigan
2024-09-11
Recruiting
Acorn Biolabs Inc.
Observational
500
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Michigan
2024-09-09
Recruiting
Kardion Inc
Not applicable
310
Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Indiana, Massachusetts
2024-09-03
Active, closed
Fractyl Health Inc.
Not applicable
315
Arizona, California, Florida, Indiana, Michigan, New Hampshire, New York, Pennsylvania
2024-09-01
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
48
Florida, Indiana, Texas
2024-08-31
Recruiting
A Study of Bleeding and Treatment in Participants With Von Willebrand Disease
NCT06610201Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Hemab ApS
Observational
200
Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Michigan
2024-08-30
Active, closed
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
NCT06331299Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
UroGen Pharma Ltd.
Phase 3
99
California, District of Columbia, Georgia, Indiana, Minnesota, New Jersey, New York, South Carolina
2024-08-29
Active, closed
Gilead Sciences
Phase 3
640
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-08-28
Recruiting
Kyverna Therapeutics
Phase 2/3
66
California, Florida, Indiana, Missouri, Oregon, Pennsylvania, Texas, Utah
2024-08-28
Active, closed
Kite, A Gilead Company
Phase 3
452
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2024-08-23
Active, closed
Kodiak Sciences Inc
Phase 3
675
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-08-23
Recruiting
AbbVie
Phase 3
675
Arkansas, California, Florida, Georgia, Idaho, Illinois, Indiana, Kentucky
2024-08-19
Active, closed
DexCom, Inc.
Not applicable
283
Colorado, Florida, Georgia, Indiana, Minnesota, Missouri, New York, North Carolina
2024-08-15
Active, closed
Genmab
Phase 3
379
California, Colorado, Georgia, Illinois, Indiana, Kansas, Kentucky, Maryland
2024-08-13
Active, closed
Genentech, Inc.
Phase 2
118
Arkansas, Colorado, Florida, Indiana, Iowa, Maryland, Massachusetts, Nebraska
2024-08-09
Recruiting
AbbVie
Phase 3
110
California, Colorado, Connecticut, Illinois, Indiana, Massachusetts, Minnesota, New York
2024-08-08
Recruiting
AbbVie
Phase 3
170
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Iowa
2024-08-05
Active, closed
BioNTech SE
Phase 2
110
Alaska, California, Florida, Illinois, Indiana, Kentucky, Minnesota, Missouri
2024-08-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
3,000
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2024-08-05
Recruiting
AstraZeneca
Phase 3
788
Arizona, California, Colorado, Florida, Illinois, Indiana, Kentucky, Maryland
2024-08-01
Active, closed
GlaxoSmithKline
Phase 3
10,212
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas
2024-08-01
Active, closed
Bausch & Lomb Incorporated
Phase 4
216
California, Florida, Georgia, Indiana, Missouri, North Carolina, Tennessee
2024-07-31
Recruiting
NovoCure GmbH
Phase 3
734
Alabama, Arizona, California, Florida, Illinois, Indiana, Kansas, Missouri
2024-07-31
Recruiting
PinkDx, Inc.
Observational
4,500
Alabama, California, Florida, Illinois, Indiana, Minnesota, Missouri, New York
2024-07-30
Active, closed
TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
NCT06137807Tricuspid Regurgitation, Tricuspid Valve Disease
P+F Products + Features USA Inc.
Not applicable
50
Arizona, California, Florida, Illinois, Indiana, Louisiana, Massachusetts, Minnesota
2024-07-23
Rows per page Showing 1–500 of 1122
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-usa/state/indiana

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 10 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,122 of those studies with a site in Indiana.

How many clinical trials are recruiting in Indiana?

562 of the 1,122 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:16 UTC sync. A further 18 have not yet opened recruitment, 518 are active but closed to new participants, and 24 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Indiana), 1,122 studies
PhaseStudiesRecruitingShare
Phase 342318837.7%
Phase 21919217%
Not applicable1547013.7%
Observational1327211.8%
Phase 180537.1%
Phase 1/276476.8%
Phase 2/336243.2%
Phase 430162.7%

Most active sponsors

Lead sponsors with the most studies (Indiana)
Lead sponsorStudiesRecruiting
Eli Lilly and Company4928
AbbVie4121
AstraZeneca4115
Janssen Research & Development, LLC3917
Merck Sharp & Dohme LLC3110
Novartis Pharmaceuticals3111
Pfizer2719
Novo Nordisk A/S2310
Hoffmann-La Roche186
Regeneron Pharmaceuticals1814
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.